Support Our Work
About the Laboratory
The Dendritic Cell Research group (DCR) is directed by Associate Professor Georgina Clark. They discover key immune markers and biological processes which will provide new diagnostic and therapeutic products for improving patient care.
The group studies DC surface molecules to determine how these molecules influence DC function and how antibodies targeting them might be used in clinical practice. A major part of our work is aimed at using the patient’s immune responses to treat haematological cancers.
We are testing our findings in preclinical models of stem cell transplantation, leukaemia, multiple myeloma, prostate cancer and other malignancies.
We are striving to develop novel immunosuppressive strategies, including our previous anti-CD83 antibody as a novel therapeutic agent. We aim to use this antibody to improve transplant outcomes, whilst preserving the patient’s ability to fight infections and cancer. Negotiations to support a clinical trial of anti-CD83 in allogeneic haematopoietic stem cell transplantation are underway.
About Our Team
Associate Professor Georgina Clark
A/Prof Clark set up Dendritic Cell Research (DCR) at the ANZAC Research Institute alongside the late Professor Derek Hart. Her interest lies in translational research developing antibodies to leucocyte surface molecules into immune therapies. The group’s translational pipeline from discovery of novel molecules (CD300 family, CD302, CD205, CD83, CMRF-56, CMRF-44) expressed by myeloid lineage cells including dendritic cells…..read more
Dr Pablo Silveira
Dr Silveira joined the Dendritic Cell Research Group in 2012, where his research is focussed on novel molecules on dendritic cells that can be used as therapeutic targets to control inflammation associated with haematopoietic stem cell transplantation, solid organ transplantation or autoimmune disease…read more
Dr Xinsheng Ju
Dr Ju re-joined Professor Derek Hart, Dendritic Cell Research group in 2014 to continue his long term interests on DC biology and targeting CD83 molecule to control graft versus host disease (GVHD) and treat haematological malignancies…. read more
Our Research Specialities
Current News
Immunology Company Kira Biotech launches with A$20M Series A Funding
Brisbane, 29 October 2019: Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders.
The round was led by OneVentures, with significant investment from IP Group and support from the Advance Queensland Business Development Fund. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies. Read More
Dendritic Cell Research
The ANZAC Research Institute
Concord Repatriation General Hospital
Gate 3, Hospital Road
Concord NSW 2139, Australia
P: +61 2 9767 9100
F: +61 2 9767 9101
E: dcr.admin@sydney.edu.au
Subscribe to our Newsletter
Subscribe to our e-newsletter and receive quarterly updates about our people, research projects, achievements and how you can help.